Filing Details
Aura Biosciences, Inc. (NASDAQ:AURA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:AURA
Aura Biosciences, Inc. (AURA) Files Quarterly Report for Q0
Aura Biosciences, Inc. (NASDAQ:AURA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 11, 2026.
At publication ·
What changed
Aura Biosciences, Inc. (NASDAQ:AURA) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Aura Biosciences, Inc. (NASDAQ: AURA) filed its quarterly 10-Q report on August 11, 2026, providing unaudited financial statements and management commentary on recent business performance.
- The company's stock trades at $8.04 with a market capitalization of $413.3 million as of the filing date.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last annual 10-K filing.
Market Context
Aura Biosciences, Inc.'s stock currently trades at $8.04 with a market capitalization of $413.3M.
The 10-Q provides Aura Biosciences, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Aura Biosciences, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AURA Stock Page
Frequently Asked Questions
Where can I read AURA's SEC filings?
Browse all filings on our AURA SEC filings page.
What types of SEC filings does Aura Biosciences, Inc. file?
Public companies like Aura Biosciences, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
